NHS platform announced to accelerate personalised cancer vaccine clinical trials
The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines
Read More
Tag: BioNTech
FDA approves Pfizer/BioNTech and Moderna’s adapted COVID-19 vaccines
The updated vaccines more closely target current circulating variants
Read More
BioNTech forms cancer immunotherapies partnership with UK Government
Collaboration will focus on providing up to 10,000 patients with personalised mRNA by 2030
Read More
Trial results for Pfizer and BioNTech’s COVID-19 vaccine for children released
The phase 2/3 trial results showed that the vaccine was effective in protecting children
Read More
Pfizer/BioNTech vaccine effective against Omicron in children five and under
Companies say that three-dose vaccine for children aged six months to five years old is 80% effective at preventing illness
Read More
Positive topline results for Pfizer/BioNTech jab in five to 11-year-olds
Results showed vaccine has favourable safety profile in this age group
Read More
Pfizer/BioNTech’s COVID-19 vaccine wins first full FDA approval
Biologics License Application approved to prevent COVID-19 in individuals 16 years of age and older
Read More
BioNTech to develop a mRNA-based malaria vaccine
Clinical trial for first vaccine candidate is planned for the end of 2022
Read More
AZ, Pfizer/BioNTech vaccines ‘highly effective’ against Delta variant
New real world data from PHE shows vaccines can protect against hospitalisation caused by variant
Read More
MHRA authorises Pfizer/BioNTech’s COVID-19 vaccine for 12- to 15-year-olds
JCVI will advise on whether this younger age group will be vaccinated routinely
Read More
EU secures 1.8 billion additional doses of Pfizer/BioNTech’s COVID-19 jab
Pfizer/BioNTech said all doses earmarked for the European Commission are planned to be manufactured in the European Union
Read More
US approves Pfizer COVID-19 vaccine for children aged 12 to 15
First COVID-19 jab to be approved for emergency use in the US for this younger age group
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
